Stockreport

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF SAN FRANCISCO, March 05, 2024 BUSINESS WIRE )--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tol [Read more]